Carroll Patrick Harrison sold $830K of HIMS

Carroll Patrick Harrison (Chief Medical Officer) sold 23,726 shares of Hims & Hers Health, Inc. (HIMS) at $35.00 ($0.83M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Carroll Patrick Harrison
Published Jun 23, 2026, 10:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The disclosed sale is a scheduled open-market transaction under a 10b5-1 plan, typically lowering interpretive weight versus discretionary selling.

02

Market read

Traders may briefly reassess near-term sentiment around insider activity, but there is no new fundamental information.

03

What to watch

The filing does not disclose any change in business outlook, guidance, or risk factors; the only actionable element is monitoring for future non-10b5-1 transactions or follow-on disclosures.

Relevance 4/10Novelty 5/10Timing: new SEC Form 4 filed 2026-06-23 (sale dated 2026-06-18)

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

SEC Form 4 shows CMO Carroll Patrick Harrison sold 23,726 shares of HIMS at $35 on 2026-06-18 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying new company-specific operational or financial information.

Market effects

Minimal; insider-sale filings rarely reset sector expectations without additional company news.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish conviction, so traders may ignore it.

Key entities

  • Hims & Hers Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Carroll Patrick Harrison

    Chief Medical Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.